Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.76 USD | +1.34% | -1.73% | +18.91% |
May. 31 | Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test | MT |
May. 31 | Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.91% | 2.06B | |
-3.17% | 8.22B | |
+6.11% | 5.72B | |
+31.98% | 5.67B | |
-10.03% | 4.11B | |
-59.94% | 2.68B | |
+11.23% | 2.68B | |
-5.14% | 2.37B | |
-7.56% | 1.8B | |
+3.07% | 1.6B |
- Stock Market
- Equities
- MYGN Stock
- News Myriad Genetics, Inc.
- Wolfe Research Initiates Myriad Genetics With Outperform Rating With $28 Price Target